Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications
Introduction Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, originally developed for the treatment of type 2 diabetes, have recently attracted attention for their potential applications in oncology. Their potential to modulate tumor metabolism and enhance responses to cancer therapies is an a...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2025-01-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/57224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841545239236444160 |
|---|---|
| author | Aldona Sokołowska Klaudia Fikas Kamil Chwaliszewski Sebastian Samuła Michał Mazur Dorota Waz Jakub Szarłowicz Zofia Goliszek Karolina Łucja Sobek Wiktoria Tabin-Barczak |
| author_facet | Aldona Sokołowska Klaudia Fikas Kamil Chwaliszewski Sebastian Samuła Michał Mazur Dorota Waz Jakub Szarłowicz Zofia Goliszek Karolina Łucja Sobek Wiktoria Tabin-Barczak |
| author_sort | Aldona Sokołowska |
| collection | DOAJ |
| description |
Introduction
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, originally developed for the treatment of type 2 diabetes, have recently attracted attention for their potential applications in oncology. Their potential to modulate tumor metabolism and enhance responses to cancer therapies is an area of increasing interest.
Aim of the study
This review aims to explore the emerging role of SGLT-2 inhibitors in cancer treatment, focusing on their mechanisms of action, preclinical findings, and early clinical evidence. By understanding the potential of these agents to alter tumor metabolism and the immune microenvironment, we can evaluate their therapeutic value in cancer management.
Material and Methods
Data were gathered from peer-reviewed articles, clinical trials, and ongoing research on the use of SGLT-2 inhibitors in combination with chemotherapy, immunotherapy, and other cancer treatments.
Description of the state of knowledge
Preclinical studies suggest that SGLT-2 inhibitors can alter cancer cell metabolism by limiting glucose availability, potentially impeding tumor growth. These agents have demonstrated promise in models of breast, prostate, and pancreatic cancers, reducing cell proliferation and enhancing the efficacy of standard cancer treatments.
Conclusions
SGLT-2 inhibitors represent a novel therapeutic strategy in oncology, with potential to improve outcomes in combination with traditional therapies. However, more extensive clinical trials are required to validate their effectiveness, optimize treatment regimens, and better understand their safety profiles in cancer patients.
|
| format | Article |
| id | doaj-art-e098241cc33045d2bb661ab44dd30b1e |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-e098241cc33045d2bb661ab44dd30b1e2025-01-12T08:22:52ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182025-01-013710.12775/QS.2025.37.57224Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical ImplicationsAldona Sokołowska0https://orcid.org/0009-0006-8723-2593Klaudia Fikas1https://orcid.org/0009-0008-1976-2941Kamil Chwaliszewski2https://orcid.org/0009-0003-7239-3122Sebastian Samuła3https://orcid.org/0009-0008-8915-4263Michał Mazur4https://orcid.org/0009-0007-3840-4325Dorota Waz5https://orcid.org/0009-0004-7484-9231Jakub Szarłowicz6https://orcid.org/0009-0006-8520-9496Zofia Goliszek7https://orcid.org/0009-0005-9881-5754Karolina Łucja Sobek8https://orcid.org/0009-0000-2551-0515Wiktoria Tabin-Barczak9https://orcid.org/0009-0003-8333-8428Kliniczny Szpital Wojewódzki Nr 2 im. Świętej Jadwigi Królowej w Rzeszowie, Lwowska 60, 35-301 RzeszówUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, PolandUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, PolandStefan Cardinal Wyszyński Provincial Specialist Hospital SPZOZ in Lublin, Aleja Kraśnicka 100, 20-718 Lublin, PolandUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandMedical Center in Łańcut, Poland Ignacego Paderewskiego 5, 37-100 Łańcut, PolandUniversity of Rzeszów al. Tadeusza Rejtana 16C, 35-310 Rzeszów, Poland Introduction Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, originally developed for the treatment of type 2 diabetes, have recently attracted attention for their potential applications in oncology. Their potential to modulate tumor metabolism and enhance responses to cancer therapies is an area of increasing interest. Aim of the study This review aims to explore the emerging role of SGLT-2 inhibitors in cancer treatment, focusing on their mechanisms of action, preclinical findings, and early clinical evidence. By understanding the potential of these agents to alter tumor metabolism and the immune microenvironment, we can evaluate their therapeutic value in cancer management. Material and Methods Data were gathered from peer-reviewed articles, clinical trials, and ongoing research on the use of SGLT-2 inhibitors in combination with chemotherapy, immunotherapy, and other cancer treatments. Description of the state of knowledge Preclinical studies suggest that SGLT-2 inhibitors can alter cancer cell metabolism by limiting glucose availability, potentially impeding tumor growth. These agents have demonstrated promise in models of breast, prostate, and pancreatic cancers, reducing cell proliferation and enhancing the efficacy of standard cancer treatments. Conclusions SGLT-2 inhibitors represent a novel therapeutic strategy in oncology, with potential to improve outcomes in combination with traditional therapies. However, more extensive clinical trials are required to validate their effectiveness, optimize treatment regimens, and better understand their safety profiles in cancer patients. https://apcz.umk.pl/QS/article/view/57224SGLT-2 inhibitorstype 2 diabetescardiovascular protectionrenal outcomesathletic performancecancer therapy |
| spellingShingle | Aldona Sokołowska Klaudia Fikas Kamil Chwaliszewski Sebastian Samuła Michał Mazur Dorota Waz Jakub Szarłowicz Zofia Goliszek Karolina Łucja Sobek Wiktoria Tabin-Barczak Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications Quality in Sport SGLT-2 inhibitors type 2 diabetes cardiovascular protection renal outcomes athletic performance cancer therapy |
| title | Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications |
| title_full | Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications |
| title_fullStr | Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications |
| title_full_unstemmed | Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications |
| title_short | Exploring the Potential of SGLT-2 Inhibitors in Cancer Treatment: Mechanisms, Preclinical Findings, and Clinical Implications |
| title_sort | exploring the potential of sglt 2 inhibitors in cancer treatment mechanisms preclinical findings and clinical implications |
| topic | SGLT-2 inhibitors type 2 diabetes cardiovascular protection renal outcomes athletic performance cancer therapy |
| url | https://apcz.umk.pl/QS/article/view/57224 |
| work_keys_str_mv | AT aldonasokołowska exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT klaudiafikas exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT kamilchwaliszewski exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT sebastiansamuła exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT michałmazur exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT dorotawaz exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT jakubszarłowicz exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT zofiagoliszek exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT karolinałucjasobek exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications AT wiktoriatabinbarczak exploringthepotentialofsglt2inhibitorsincancertreatmentmechanismspreclinicalfindingsandclinicalimplications |